Comparison of the EPOS 2020 and POLINA 2.0 guidelines for indicating biologic treatment in adults with chronic rhinosinusitis and nasal polyps
The differences among the POLINA 2.0 and the EPOS 2020 guidelines appear to have an impact in the proportion of patients eligible for biological therapies, with the former being stricter. Increasing the number of prior surgeries required, reduces the proportion of patients eligible for monoclonal antibodies prescription.
Authors
- José María Caballero (ORCID: https://orcid.org/0000-0001-6826-0966)
- Núria Padullés Zamora (ORCID: https://orcid.org/0000-0002-8783-3042)
- Mariana Muñoz Esquerre
- Alejandro Portillo
- Xavier González-Compta (ORCID: https://orcid.org/0000-0002-5891-322X)
- Isam Alobid (ORCID: https://orcid.org/0000-0001-7204-5599)
- Mireia Golet Fors (ORCID: https://orcid.org/0000-0002-8697-1320)
- J. Sastre (ORCID: https://orcid.org/0000-0003-4689-6837)
Institutions
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Hospital Quirón Teknon (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Universidad Autónoma de Madrid (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Acta Otorrinolaringologica (English Edition)
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.otoeng.2025.512224
- Primary Topic
- Sinusitis and nasal conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00